Home Tags Dxd

Tag: Dxd

The Highs, Lows, and Resurgence of Antibody-drug Conjugates

Antibody drug conjugates (ADCs) offer a way to deliver a cytotoxic or an immuno-stimulatory payload directly to tumors to maximize the anti-tumor efficacy of the payload with reduced systemic toxicities. The development of ADCs has occurred over several decades. ADCs have been through several highs and lows where there was substantial excitement for the promise ADCs hold only to be followed by disinterest when there were disappointing results in the clinic. This resulted in several companies abandoning their internal ADC development efforts. Twelve ADCs globally have been approved to treat hematologic or solid tumors. The renewed interest in ADCs, is due, in part, to the recent clinical success of ADCs, the development of improved ADC technologies, and the identification of new ADC targets.
General images of ESMO 2019 Congress being held in Barcelona, Spain, September 27 - October 1, 2019. Courtesy European Society for Medical Oncology (ESMO). Used with Permission.

Trastuzumab Deruxtecan Shows Clinically Meaningful Survival Across Multiple HER2 Expressing...

Positive results from the ongoing DESTINY-PanTumor02 phase 2 trial (ClinicalTrials.gov Identifier: NCT04482309) * confirms that trastuzumab deruxtecan ([fam-trastuzumab deruxtecan-nxki in the U.S. only] Enhertu®; Daiichi Sankyo and AstraZeneca) continues to demonstrate clinically meaningful and durable responses, leading to a clinically meaningful survival benefit in previously treated patients across multiple human epidermal growth factor receptor 2 (HER2) expressing advanced solid tumors.
General Views of the 55th Annual Meeting meeting of the American Society of Clinical Oncology. Photo Courtesy: © ASCO/Nick Agro 2019.

Preliminary Phase I Data for U3-1402 Shows Manageable Safety and Reduction...

Preliminary results from the dose escalation part of the phase I study with U3-1402, an investigational and potential first-in-class HER3 targeting antibody-drug conjugate or...

Breakthrough Therapy Designation for DS-8201 Confirms the Potential to Offer Substantial...

The U.S. Food and Drug Administration (FDA) earlier today confirmed that it has granted Breakthrough Therapy designation to DS-8201, an investigational HER2-targeting antibody-drug conjugate...

X